shutterstock_mitochondria_Web-824x549.jp

ABOUT US

A World-Changing Discovery

Discovered and made in the USA🇺🇸

 

CoR has created a unique therapeutic strategy that rejuvenates mitochondria cells and regulates stem cells. It is designed to restore damaged mitochondrial function.

 

This innovative approach to preventing, delaying, and treating human degeneration can potentially slow or reverse the aging process! https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779179/

 

70% of human diseases are related to mitochondrial dysfunction. 

 

Adenosine triphosphate (ATP), an energy-rich and highly efficient molecular machine, is the only energy source that can do the biological work of using the energy stored in food.  ATP, also known as an energy currency, is the key to full mitochondrial function. 

 

CoR is now in the development stage as a pharmaceutical and nutraceutical therapeutic for human and animal degeneration diseases.

 

CoR works on the Redox Reaction in the mitochondria, the center of converting nutrition for increasing ATP production to provide the vital energy for cellular functions. 

 

OUR TECHNOLOGY

CoR   -   Cofactor R

The World's 4th Organic Redox Cofactor Discovery

 A new cofactor that has proven to be the most effective 
 

Our company has discovered and identified CoR, Cofactor R, a new and unique transmembrane oxidoreductase that acts on a sulfur group of donors, with FAD as the Carrier/ Acceptor. This enzyme catalyzes the transfer of electrons from one molecule to another in the mitochondria. 

CoR involves the Phase Transfer Property, transferring 2 electrons and multiple complicated catalyzed redox reactions including catalysis carbohydrate, fatty acid, and amino acid.

The required physiological Carrier/Acceptor of CoR is FAD. FAD is a more energetic oxidizing agent than NAD.

In contrast, PQQ,  the world’s 3rd redox cofactor, has not yet identified its physiological carrier/acceptor even after eighty years of study.

Lab Work
 
Handshake
Marble Surface

Investors

Mito LiuXia Pharma has secured start-up funding to support the generation of preliminary data and the IP filing for the company. Initial investments have been used for the significant advances already achieved. Our activities and studies of this lead compound have yielded positive data for mitochondrion energy homeostasis. Our company has been successful in securing its core intellectual property. 

We are currently seeking new funding for advancing our research and development needs.

Analysing Data
Marble Surface

Partners

Mito LiuXia Pharma is currently seeking strategic partners to further develop its unique, innovative intellectual property. The company has already established collaborative relationships with individual partners and universities to allow for more study and advancement of its IP technology. 

At this time, Mito LiuXia Pharma utilizes a virtual corporate model deployment strategy for its core intellectual property. The company is seeking to build relationships in order to further advance the development of its IP technology into the broader markets of drug development, supplements, food additives, nutrition, dietary foods, and more.

Giving a Presentation
Marble Surface

Licensing

Mito LiuXia Pharma’s unique, innovative IP proposes a groundbreaking and globalized pharmaceutical and nutraceutical composition.  

 

The company is open to exploring and entering into licensing agreements. Please contact us for further questions and information. 

 

MEET OUR TEAM

Shaoyun Liu

  • LinkedIn

Founder and CEO

Peter G. Espina

  • LinkedIn

COO

Iwao Ojima, Ph.D.

Scientific Advisory

Shanni Zhou

  • LinkedIn

Business Development Manager

Affiliations

 

CONTACT US

1333 Stony Brook Rd, Stony Brook, NY 11790

  • LinkedIn
  • Facebook

Mito LiuXiaPharma

Long Island High-Technology Incubator of Stony Brook University

25 Health Science Drive

Mail Box: 410

Stony Brook NY 11790

Phone: (631) 292-9008

Fax: (631) 621-0259

drliu@mitoliu.com

© Mito Liuxa Pharma all rights reserved